Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (171-180 of 238) with videos related to

Pageof 24
Sort By:
Blood Cells, Molecules & Diseases|June 4, 2017
Response to request by journal editorship from Blood Cells, Molecules and Diseases in reference to a "Dear Editor" letter to the Pastores et al. paper, 2016Gregory M Pastores, Hadhami Ben Turkia, Derlis E Gonzalez, et al.
Blood Cells, Molecules & Diseases|August 6, 2010
Preimplantation genetic diagnosis (PGD) for a treatable disorder: Gaucher disease type 1 as a modelGheona Altarescu, Paul Renbaum, Talia Eldar-Geva, et al.
Blood|July 5, 2007
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacementDeborah Elstein, Altoon Dweck, Drorit Attias, et al.
International Journal of Molecular Sciences|June 26, 2019
Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher DiseaseNoa Hurvitz, Tama Dinur, Michal Becker-Cohen, et al.
American Journal of Hematology|April 23, 2016
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Suma P Shankar, Milan Petakov, et al.
International Journal of Molecular Sciences|May 13, 2026
Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher DiseaseTama Dinur, Peter Bauer, Sabine Schroeder, et al.
Molecular Biology International|January 16, 2013
Prevention of lysosomal storage diseases and derivation of mutant stem cell lines by preimplantation genetic diagnosisGheona Altarescu, Rachel Beeri, Rachel Eiges, et al.
The Journal of Obstetrics and Gynaecology Research|March 12, 2014
Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher diseaseDeborah Elstein, Derralynn Hughes, Ozlem Goker-Alpan, et al.
Journal of Clinical Medicine|May 25, 2024
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) RegistryPatrick Deegan, Heather Lau, Deborah Elstein, et al.
Haematologica|February 1, 2020
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant dataTatiana Raskovalova, Patrick B Deegan, Pramod K Mistry, et al.
Pageof 24

Showing results (171-180 of 238) with videos related to

Sort By:
Pageof 24
Blood Cells, Molecules & Diseases|June 4, 2017
Response to request by journal editorship from Blood Cells, Molecules and Diseases in reference to a "Dear Editor" letter to the Pastores et al. paper, 2016Gregory M Pastores, Hadhami Ben Turkia, Derlis E Gonzalez, et al.
Blood Cells, Molecules & Diseases|August 6, 2010
Preimplantation genetic diagnosis (PGD) for a treatable disorder: Gaucher disease type 1 as a modelGheona Altarescu, Paul Renbaum, Talia Eldar-Geva, et al.
Blood|July 5, 2007
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacementDeborah Elstein, Altoon Dweck, Drorit Attias, et al.
International Journal of Molecular Sciences|June 26, 2019
Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher DiseaseNoa Hurvitz, Tama Dinur, Michal Becker-Cohen, et al.
American Journal of Hematology|April 23, 2016
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Suma P Shankar, Milan Petakov, et al.
International Journal of Molecular Sciences|May 13, 2026
Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher DiseaseTama Dinur, Peter Bauer, Sabine Schroeder, et al.
Molecular Biology International|January 16, 2013
Prevention of lysosomal storage diseases and derivation of mutant stem cell lines by preimplantation genetic diagnosisGheona Altarescu, Rachel Beeri, Rachel Eiges, et al.
The Journal of Obstetrics and Gynaecology Research|March 12, 2014
Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher diseaseDeborah Elstein, Derralynn Hughes, Ozlem Goker-Alpan, et al.
Journal of Clinical Medicine|May 25, 2024
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) RegistryPatrick Deegan, Heather Lau, Deborah Elstein, et al.
Haematologica|February 1, 2020
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant dataTatiana Raskovalova, Patrick B Deegan, Pramod K Mistry, et al.
Pageof 24